Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-437886
Filing Date
2013-11-12
Accepted
2013-11-12 13:55:21
Documents
12
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d596473d10q.htm 10-Q 616280
2 EX-10.1 d596473dex101.htm EX-10.1 11801
3 EX-31.1 d596473dex311.htm EX-31.1 6245
4 EX-31.2 d596473dex312.htm EX-31.2 6221
5 EX-32.1 d596473dex321.htm EX-32.1 3075
6 EX-32.2 d596473dex322.htm EX-32.2 3036
  Complete submission text file 0001193125-13-437886.txt   3036829

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT orex-20130930.xml EX-101.INS 369338
8 XBRL TAXONOMY EXTENSION SCHEMA orex-20130930.xsd EX-101.SCH 29702
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE orex-20130930_cal.xml EX-101.CAL 43465
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE orex-20130930_def.xml EX-101.DEF 155732
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE orex-20130930_lab.xml EX-101.LAB 218608
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE orex-20130930_pre.xml EX-101.PRE 182775
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33415 | Film No.: 131209317
SIC: 2834 Pharmaceutical Preparations